SCHEMBL20938003

SCHEMBL20938003

O=C(NCc1ccc(F)c(F)c1)c1cccnc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.69
NPC1 O15118 3/20 0.68
HPGD P15428 1/20 0.62
THRB P10828 1/20 0.56
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56
MAPT P10636 1/20 0.55
NAMPT P43490 1/20 0.53
GAA P10253 2/20 0.53
MEN1 O00255 2/20 0.52
RAB9A P51151 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5079750 0.85 CXCR4 (0.58) TSHRNPC1HPGDHDAC1NAMPT
SCHEMBL1568038 0.83 L3MBTL1 (0.70) NAMPTGAAL3MBTL1
SCHEMBL3459872 0.83 ERCC1 (0.65) NPC1HDAC3HDAC4HDAC1HDAC7
SCHEMBL30309978 0.81 SMN1; SMN2 (0.51) TSHRNPC1HDAC1SMN1; SMN2L3MBTL1
SCHEMBL7082686 0.81 TSHR (0.73) TSHRNPC1THRBMAPTNAMPT
SCHEMBL3918322 0.80 TSHR (0.76) TSHRNPC1HPGDTHRBHDAC3
SCHEMBL17727698 0.80 VNN1 (0.47) TSHRNPC1HDAC1SMN1; SMN2L3MBTL1
SCHEMBL354041 0.80 TSHR (0.76) TSHRNPC1THRBHDAC3HDAC4
SCHEMBL19028142 0.80 TSHR (0.76) TSHRNPC1HPGDTHRBHDAC3
SCHEMBL6167737 0.79 TSHR (0.74) TSHRNPC1HPGDTHRBHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466929-B1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS MILLENNIUM PHARM INC (US) 2023-09-06 EP disclosed
US-20190119268-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119268-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 TSHR 3323/4885NPC1 1006/4885HPGD 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.